The compounding effects of hepatitis c infection with liver cirrhosis, hepatocellular carcinoma, and budd-chiari syndrome in fatal gastrointestinal haemorrhage

Pathology ◽  
2020 ◽  
Vol 52 ◽  
pp. S103
Author(s):  
Alexandra Kullen
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Hepatitis C ◽  
Gastrointestinal Haemorrhage ◽  
Budd Chiari Syndrome ◽  
Hepatitis C Infection ◽  
Chiari Syndrome

scholarly journals Thrombophilic Genetic Factors PAI-1, MTHFRC677T, V Leiden 506Q, and Prothrombin 20210A in Noncirrhotic Portal Vein Thrombosis and Budd-Chiari Syndrome in a Caucasian Population

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Mario D’Amico ◽  
Pietro Sammarco ◽  
Linda Pasta
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Genetic Factors ◽  
Healthy Controls ◽  
Budd Chiari Syndrome ◽  
Vein Thrombosis ◽  
Chiari Syndrome ◽  
Hardy Weinberg Equilibrium ◽  
Pai 1 ◽  
Prothrombin 20210A

Thrombophilic genetic factors PAI-1, MTHFRC677T, V Leiden 506Q, and Prothrombin 20210A were studied as risk factors in 235 Caucasian subjects: 85 patients with abdominal thrombosis (54 with portal vein thrombosis (PVT) and 31 with Budd-Chiari syndrome (BCS) without liver cirrhosis or hepatocellular carcinoma) and 150 blood bank donors. Seventy-five patients with PVT/BCS showed associated disease or particular clinical status (46 PVT/29 BCS): 37 myeloproliferative neoplasm (20 PVT/17 BCS), 12 abdominal surgery (10 PVT/2 BCS), 10 contraception or pregnancy (6 PVT/4 BCS), 7 abdominal acute disease (6 PVT/1 BCS), and 9 chronic disease (4 PVT/5 BCS); ten patients did not present any association (8 PVT/2 BCS). PAI-14G-4G, MTHFR677TT, and V Leiden 506Q were significantly frequent (OR 95% CI andχ2test withPvalue) in abdominal thrombosis; in these patients PAI-14G-4G and MTHFR677TT distributions deviated from that expected from a population in the Hardy-Weinberg equilibrium (PAI-1:χ2=13.8,P<0.001; MTHFR677:χ2=7.1,P<0.01), whereas the equilibrium was respected in healthy controls. V Leiden Q506 and Prothrombin 20210A were in the Hardy-Weinberg equilibrium both in patients with abdominal thrombosis and healthy controls. Our study shows an important role of PAI-14G-4G and MTHFR677TT in abdominal thrombosis without liver cirrhosis or hepatocellular carcinoma.

scholarly journals The expression of microRNA-331-3p and microRNA-23b3 in Egyptian patients with early-stage hepatocellular carcinoma in hepatitis C-related liver cirrhosis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Reham A. Aboelwafa ◽  
Walid Ismail Ellakany ◽  
Marwa A. Gamaleldin ◽  
Marwa A. Saad
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Hepatitis C ◽  
Early Stage ◽  
Group Iii ◽  
Real Time Quantitative Pcr ◽  
Early Stages ◽  
Group I ◽  
Egyptian Patients ◽  
Cirrhotic Patients

Abstract Background Hepatocellular carcinoma and hepatitis C are strongly associated. The current work aimed to study the expression levels of microRNA-331-3p and microRNA-23b-3p as propable biomarkers for detecting liver cancer (HCC) at its early stages in patients with HCV-related liver cirrhosis. The current prospective study included two hundred participants, divided into three groups: group I, 100 patients with HCV-related liver cirrhosis; group II, 50 HCC patients at early stages; and group III, 50 apparentlyhealthy controls. All patients had routine laboratory workup and ultrasound hepatic assessment. Values of microRNA-331-3p and microRNA-23b-3p were measured by real-time quantitative PCR. Results Levels of miR-331-3p were significantly higher in HCC patients than in cirrhotic patients and controls (p < 0.001), while levels of miR-23b-3p were significantly lower in HCC patients compared to cirrhotics and controls (p < 0.001). ROC curve revealed that miR-23b-3p had 80% sensitivity and 74% specificity, miR-331-3p had 66% sensitivity and 61% specificity, and AFP had 64% sensitivity and 61% specificity of 61% in discrimination between HCC patients from controls. Conclusion Serum miR-23b-3p is a more effective predictor than miR-331-3p and AFP for the development of hepatocellular carcinoma in hepatitis C (HCV)-related cirrhotic patients.

Characteristic clinical features of hepatocellular carcinoma associated with Budd???Chiari syndrome

2004 ◽  
pp. 319-324 ◽  
Author(s):  
Sang Hyo Shin ◽  
Young-Hwa Chung ◽  
Dong Dae Suh ◽  
Jung Woo Shin ◽  
Myoung Kuk Jang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Features ◽  
Budd Chiari Syndrome ◽  
Chiari Syndrome

scholarly journals Budd-Chiari Syndrome in a Patient with Hepatitis C

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Joseph Frankl ◽  
Charles Hennemeyer ◽  
Michael S. Flores ◽  
Archita P. Desai
Keyword(s):  
Portal Hypertension ◽  
Hepatitis C ◽  
Signs And Symptoms ◽  
Venous Occlusion ◽  
Decompensated Cirrhosis ◽  
Hepatic Veins ◽  
Budd Chiari Syndrome ◽  
Portosystemic Shunting ◽  
Chiari Syndrome

Chronic Budd-Chiari syndrome can present with cirrhosis and signs and symptoms similar to those of other chronic liver diseases. We present a case of Budd-Chiari syndrome discovered during attempted transjugular intrahepatic portosystemic shunting in a patient with decompensated cirrhosis believed to be secondary to hepatitis C. Although the patient had hepatocellular carcinoma, the Budd-Chiari syndrome was a primary disease due to hepatic venous webs. Angioplasty was performed in this case, which resolved the patient’s symptoms related to portal hypertension. Follow-up venography 5 months after angioplasty demonstrated continued patency of the hepatic veins. A biopsy was obtained in the same setting, which showed centrilobular fibrosis indicating that venous occlusion was indeed the cause of cirrhosis. It is important to consider a second disease when treating a patient with difficult to manage portal hypertension.

Sign in / Sign up

Export Citation Format

Share Document